Claims
- 1. An improvement in a device for delivering drug to the fluid environment of the gastrointestinal tract, wherein the device comprises:
- (a) a wall comprising an exterior surface that faces the environment, said wall comprising a composition permeable to the passage of fluid, which wall surrounds;
- (b) a compartment;
- (c) a drug in the compartment;
- (d) exit means in the wall for delivering the drug from the compartment;
- (e) an enteric coat on the exterior wall surface which faces the fluid environment for substantially delaying the delivery of drug from the device, and wherein the improvement comprises;
- (f) hydrophobic compound present in excess of its solubility in the exterior enteric coat which faces the fluid environment for substantially preventing the passage of fluid through the enteric coat.
- 2. The improvement in a device for delivering the drug to the fluid environment according to claim 1, wherein the hydrophobic compound is present in from 1 weight percent to 50 weight percent in the exterior enteric coat.
- 3. The improvement in a device for delivering the drug to the fluid environment according to claim 1, wherein the drug is a member selected from the group consisting of adrenocorticosteroid, hydrocortisone, prednisolone, prednisolone phosphate, prednisolone sulfate, prednisolone metasulpho-benzoate sodium, prednisolone sodium, prednisolone sodium phosphate, corticosteroid, beclomethasone, beclomethasone acetate, beclomethasone valerate, beclomethasone propionate, and beclomethasone dipropionate.
- 4. The improvement in the device for delivering the drug to the fluid environment of the gastrointestinal tract, according to claim 1, wherein the drug in the compartment comprises a member selected from the group consisting of salicylazosulfapyridine, hydrocortisone, prednisolone, prednisone, and cyclosporin.
- 5. An improvement in a device for delivering the drug to the fluid environment of the gastrointestinal tract, wherein the device comprises:
- (a) a wall comprising an exterior surface that faces the environment, said wall comprising a composition permeable to the passage of fluid, which wall surrounds;
- (b) a compartment;
- (c) a drug in the compartment;
- (d) exit means in the wall for delivering the drug from the compartment;
- (e) an enteric coat on the exterior wall surface which faces the fluid environment for substantially delaying the delivery of drug from the device, and wherein the improvement comprises;
- (f) a hydrophobic compound present in excess of its solubility in the exterior enteric coat which faces the fluid environment for substantially preventing the passage of fluid through the enteric coat, which hydrophobic compound comprises a member selected from the group consisting of ethylmethacrylate-butylmethacrylate-methylmethacrylate copolymer, methacrylic acid-methylmethacrylate copolymer trimethylammoniumethyl-methacrylatechloride-methylmethacrylate-ethylacrylate copolymer, and ethylacryylate-methylmethacrylate copolymer.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a division of Ser. No. 07/498,121, filed on Mar. 23, 1990, now U.S. Pat. No. 5,178,866, which is incorporated herein by reference, and benefit is claimed of its filing date.
US Referenced Citations (9)
Divisions (1)
|
Number |
Date |
Country |
Parent |
498121 |
Mar 1990 |
|